Optimized small scale automated preparation and quality control of [68Ga]Ga-DOTA-MGS5 and [177Lu]Lu-DOTA-MGS5 for clinical application
This study validates an optimized, automated synthesis protocol for the clinical production of [68Ga]Ga-DOTA-MGS5 and [177Lu]Lu-DOTA-MGS5 theranostic agents, demonstrating that the addition of ascorbic acid effectively mitigates radiolysis to ensure high purity and stability without the need for complex purification steps.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
In the world of modern medicine, doctors are increasingly turning to a strategy called theranostics, a blend of therapy and diagnostics that allows them to see a disease and treat it with the same tool. This approach relies on tiny molecules that act like guided missiles, seeking out specific receptors on the surface of cancer cells. Once these molecules find their target, they can be attached to radioactive atoms. If the atom emits a signal that a camera can detect, doctors can map the cancer's location. If the atom releases energy that destroys tissue, the same molecule can deliver a lethal dose directly to the tumor while sparing healthy surroundings. One promising target for this strategy is a receptor found on certain aggressive cancers, such as medullary thyroid cancer and small cell lung cancer. To reach this target, researchers use a peptide, a short chain of amino acids, that naturally binds to this receptor. By attaching a radioactive metal to this peptide, they create a drug that can both image and treat the disease. However, making these drugs is a delicate process. The high energy of the radioactive atoms can damage the delicate peptide structure during production, creating unwanted byproducts that might reduce the drug's effectiveness or safety.
Researchers at the Medical University of Innsbruck have developed a streamlined, automated method to produce two versions of this promising drug, one labeled with gallium-68 for imaging and the other with lutetium-177 for therapy. Their goal was to simplify the manufacturing process by removing complex purification steps that had previously been necessary, while ensuring the final product remained pure and stable. In their previous work, the team used a multi-step process that involved concentrating the radioactive liquid and filtering the final product to remove impurities. While effective, this approach was time-consuming and generated more radioactive waste. The new study validates a faster, purification-free workflow that relies on a modular robotic system to mix the ingredients and heat them to create the final drug. The key challenge in this simplified approach was managing radiolysis, a process where the intense radiation breaks down the chemical bonds of the peptide, creating oxidized side products. To solve this, the team tested adding different protective agents to the mixture. They found that adding a small amount of ascorbic acid, a common form of vitamin C, acted as a shield, absorbing the damaging energy and preventing the peptide from breaking apart.
The team successfully produced nine batches of the gallium-68 version and three batches of the lutetium-177 version using this new method. For the gallium version, the addition of 0.1% ascorbic acid was crucial. Without it, nearly 10% of the product consisted of damaged, oxidized peptides. With the vitamin C added, the purity of the main drug rose to over 96%, and the product remained stable for at least two hours, which is sufficient for clinical use. The lutetium version, which is used for therapy and has a longer lifespan, showed even greater stability. Even after 24 hours, the drug remained highly pure, with less than 3% of the peptide showing signs of radiation damage. The researchers also took great care to identify every possible impurity in the final product. They discovered that trace amounts of other metals, such as iron and zinc, sometimes present in the equipment or water, could also attach to the peptide. However, they confirmed that these metal-peptide combinations still bound effectively to the cancer receptors, meaning they would not interfere with the drug's ability to find the tumor. Furthermore, they used advanced mass spectrometry to analyze the damaged peptides, confirming that the radiation primarily caused oxidation of specific amino acids within the chain, but that the protective agent kept these levels low enough to be safe.
By eliminating the need for post-production purification, the new process reduces the time required to make the drug to about 24 minutes for the gallium version and 30 minutes for the lutetium version. This efficiency not only speeds up the workflow but also reduces the volume of radioactive waste generated, as fewer disposable filters and cartridges are needed. The study established strict safety criteria for the final product, including tests for sterility and the absence of bacterial toxins, all of which the new batches passed. The researchers demonstrated that a simpler, more direct manufacturing route does not have to come at the cost of quality. By carefully controlling the reaction environment and using a simple antioxidant, they created a robust system that produces high-quality radiopharmaceuticals suitable for routine clinical use. This work provides a reliable foundation for bringing these targeted cancer treatments to more patients, ensuring that the drugs are ready quickly, remain potent, and are free from harmful impurities.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.